```
L1            0 S US 20060210624/PN
L2            0 S US 20060210624/PN

     FILE 'REGISTRY' ENTERED AT 15:32:38 ON 05 JUL 2009
                 E OLANZAPINE/RN
                 E OLANZAPINE/CN
                 SET EXPAND CONTINUOUS
L3            1 S E3
                 E BF2649/CN
                 E BF 2649/CN
L4            1 S E27
                 E RISPERIDONE/CN
L5            1 S E39
                 E ARIPIPRAZOLE/CN
L6            1 S E51

     FILE 'CAPLUS' ENTERED AT 15:35:35 ON 05 JUL 2009
L7            1 S L3 AND L4
L8         1452 S L3 AND (L5 OR L6)
L9          357 S L8 AND (PY<2003 OR AY<2003 OR PRY<2003)
L10         245 S L8 AND (SIDE EFFECT?)
L11         231 S L10 AND (?PSYCHOTIC? OR ?DEPRESSANT?)
L12          67 S L11 AND (APPETITE? OR WEIGHT?)
L13          11 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)
L14           1 S L4 AND (L5 OR L6)
L15           2 S L4 AND (?DEPRESSANT? OR ?PSYCHOTIC? OR NEUROLEPTIC?)
L16           2 S L4 AND (ANTIDEPRESSANT? OR ANTIPSYCHOTIC?)
L17           0 S L16 AND (PY<2003 OR AY<2003 OR PRY<2003)
L18           0 S L4 AND (WEIGHT (L) GAIN?)
L19           1 S L4 AND (APPETITE? OR WEIGHT?)
L20           1 S L4 AND (OBES? OR OVERWEIGHT?)
L21           0 S L20 NOT L19
L22           3 S L4 AND (COGNIT?)
L23           0 S L22 AND (PY<2003 OR AY<2003 OR PRY<2003)
L24           2 S L4 AND (?ANXIETY OR ?ANXIO? OR ?PSYCH?)
L25           0 S L24 AND (PY<2003 OR AY<2003 OR PRY<2003)
L26           0 S L4 AND (?EMOTION? OR NEUROLOGIC?)
L27           5 S L4
L28           0 S L4 AND (PY,2003 OR AY<2003 OR PRY<2003)
L29           0 S L4 AND (PY<2003 OR AY<2003 OR PRY<2003)

     FILE 'REGISTRY' ENTERED AT 15:50:35 ON 05 JUL 2009
                 E CIPROXIDINE/CN
L30           1 S E63

                 E BF 2649/CN
                 SET EXPAND CONTINUOUS
L1            1 S E3
L2              STRUCTURE UPLOADED
L3         1425 S L2 SSS FULL

     FILE 'CAPLUS' ENTERED AT 07:53:22 ON 06 JUL 2009
L4          170 S L3
L5           10 S L3 AND HISTAMINE?
L6            8 S L5 AND (PY<2003 OR AY<2003 OR PRY<2003)

     FILE 'REGISTRY' ENTERED AT 07:55:44 ON 06 JUL 2009
```

```
                E 1129260-21-4/RN
L7              1 S E15
                E 1129275-24-6/RN
L8              1 S E27
                E 1129247-23-9/RN
L9              1 S E39
                E 1129266-95-0/RN
L10             1 S E51
                E 1129303-48-5/RN
L11             1 S E63
                E 1129304-94-9/RN
                E 1129304-59-1/RN
L12             1 S E87
                E 1129247-84-2/RN
L13             1 S E99
                E 1129305-30-1/RN
L14             1 S E111

     FILE 'CAPLUS' ENTERED AT 08:02:46 ON 06 JUL 2009
L15             1 S WO 2005000315/PN

L15  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   New psychiatric drug formulation with an antipsychotic or
antidepressant
     and an histamine H3 receptor antagonist for the prevention of
psychotropic
     adverse effects
ACCESSION NUMBER:         2005:589  CAPLUS  Full-text
DOCUMENT NUMBER:          142:79960
TITLE:                    New psychiatric drug formulation with an
antipsychotic
                          or antidepressant and an histamine H3 receptor
                          antagonist for the prevention of psychotropic
adverse
                          effects
INVENTOR(S):              Schwartz, Jean Charles; Rousseau Lecomte,
Jeanne Marie
PATENT ASSIGNEE(S):       Bioprojet, Fr.
SOURCE:                   Fr. Demande, 32 pp.
                          CODEN: FRXXBL
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    -----
---
     FR 2856596            A1    20041231    FR 2003-7836
20030627
     FR 2856596            B1    20070427
     CA 2530381            A1    20050106    CA 2004-2530381
20040625
     WO 2005000315         A1    20050106    WO 2004-FR1628
20040625 <--
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA,
CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1641461 A1 20060405 EP 2004-767475 20040625

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

JP 2007516160 T 20070621 JP 2006-516331 20040625

MX 2005013877 A 20060313 MX 2005-13877 20051216

US 20060210624 A1 20060921 US 2005-562396 20051227

PRIORITY APPLN. INFO.: FR 2003-7836 A 20030627

WO 2004-FR1628 W 20040625

FILE 'REGISTRY' ENTERED AT 08:03:23 ON 06 JUL 2009

L16 1 S 5786-21-0/RN

L16 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN

RN 5786-21-0 REGISTRY

CN 5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)- (CA INDEX NAME)

OTHER NAMES:

CN 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine

CN Asaleptin

CN Azaleptine

CN Cloril

CN Clozapin

CN Clozapine

CN Clozaril

CN Fazaclo

CN HF 1854

CN Iprox

CN Klozapol

CN Leponex
MF C18 H19 Cl N4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,
DDFU, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*,
PHAR, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2,
USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent;
Report
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic);
RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); FORM (Formation, nonpreparative); PREP (Preparation); PROC
(Process); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
(Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
(Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical
study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP
(Preparation); PROC (Process); PRP (Properties); USES (Uses)



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

```
     FILE 'REGISTRY' ENTERED AT 08:03:38 ON 06 JUL 2009
L17           1 S 85650-52-8/RN

L17  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   85650-52-8  REGISTRY
CN   Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine,
     1,2,3,4,10,14b-hexahydro-2-methyl-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine,
     1,2,3,4,10,14b-hexahydro-2-methyl-, (±)-
OTHER NAMES:
CN   6-Azamianserin
CN   Avanza
CN   Mepirzapin
CN   Mepirzepine
CN   Mirtabene
CN   Mirtaz 15
CN   Mirtazapine
CN   Mirtazepine
CN   Mirtazipine
CN   Norset
CN   Org 3770
CN   Promyrtil
CN   Remergil
CN   Remergon
CN   Remeron
CN   Rexer
CN   Zispin
DR   61337-67-5, 82601-27-2
MF   C17 H19 N3
CI   COM
SR   European Union (EU)
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
BIOSIS,
       BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,
CSCHEM,
       DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
IMSDRUGNEWS,
       IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-
OHS,
       PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER,
USAN,
       USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal;
Patent;
       Report
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological
study);
       PREP (Preparation); PROC (Process); PRP (Properties); RACT
(Reactant or
       reagent); USES (Uses); NORL (No role in record)
RLD.P  Roles for non-specific derivatives from patents:  ANST
(Analytical
```

study); BIOL (Biological study); PRP (Properties); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP
(Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study); PREP (Preparation)



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:03:55 ON 06 JUL 2009
L18 1 S 106266-06-2/RN

L18 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 106266-06-2 REGISTRY
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-
1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1,2-Benzisoxazole, 4H-pyrido[1,2-a]pyrimidin-4-one deriv.
OTHER NAMES:
CN Apexidone
CN Psychodal
CN R 64766
CN Rispadal
CN Risperdal
CN Risperdal Consta
CN Risperidal
CN Risperidone
CN Spiron
MF C23 H27 F N4 O2
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU,
DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT,
IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS,
RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: WHO
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic);
RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); PREP (Preparation); PROC (Process); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); MSC (Miscellaneous); NANO (Nanomaterial); OCCU (Occurrence);
PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
study); PROC (Process); PRP (Properties); USES (Uses)



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:04:11 ON 06 JUL 2009
L19 1 S 111974-69-7/RN

L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 111974-69-7 REGISTRY
CN Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Dibenzo[b,f][1,4]thiazepine, ethanol deriv.
OTHER NAMES:
CN Quetiapine
DR 264256-90-8
MF C21 H25 N3 O2 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS,
CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, HSDB*, IMSDRUGNEWS,
IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROMT,
PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,

USPATFULL
(*File contains numerically searchable property data)
DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process);
PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES
(Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); PREP (Preparation); PROC (Process); PRP (Properties); USES
(Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP
(Properties); RACT (Reactant or reagent); USES (Uses)



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:04:44 ON 06 JUL 2009
L20 1 S 132539-06-1/RN

L20 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 132539-06-1 REGISTRY
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)
OTHER NAMES:
CN Lanzac
CN LY 170053
CN Olanzapine
CN Oleanz
CN Oliza
CN Oltal
CN Zyprexa
DR 1034315-19-9
MF C17 H20 N4 S

CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
    CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE,
    IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA,
    MEDLINE, MRCK*, PATDPASPC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*,
    SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
      (*File contains numerically searchable property data)
DT.CA CAplus document type: Conference; Dissertation; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
    FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process);
    PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES
    (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
    study); FORM (Formation, nonpreparative); PREP (Preparation); PRP
    (Properties); RACT (Reactant or reagent); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
    study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC
    (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
    study); FORM (Formation, nonpreparative); PREP (Preparation); PROC
    (Process); RACT (Reactant or reagent)



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:05:12 ON 06 JUL 2009
L21 1 S 288-32-4/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:05:30 ON 06 JUL 2009
L22 1 S 362665-56-3/RN

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 362665-56-3 REGISTRY
CN Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]- (CA INDEX NAME)
OTHER NAMES:
CN 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine
CN 3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether
CN Pitolisant
MF C17 H26 Cl N O
CI COM
SR CA
LC STN Files: ADISINSIGHT, CA, CAPLUS, CASREACT, IMSDRUGNEWS, IMSRESEARCH,
PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); USES (Uses)



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 08:06:52 ON 06 JUL 2009
L23 10 S L22
L24 1 S L23 AND (PY<2003 OR AY<2003 OR PRY<2003)
L25 9189 S L16-L20
L26 2 S L23 AND L25

L26 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine monohydrochloride as a histamine H3 receptor ligand.
ACCESSION NUMBER: 2006:817672 CAPLUS Full-text
DOCUMENT NUMBER: 145:249105
TITLE: Preparation of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine monohydrochloride as a histamine H3 receptor ligand.
INVENTOR(S): Raga, Manuel, M.; Sallares, Juan; Guerrero, Marta; Guglietta, Antonio
PATENT ASSIGNEE(S): Ferrer Internacional, S. A., Spain
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006084833	A1	20060817	WO 2006-EP50703	20060206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

L26 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
TI New psychiatric drug formulation with an antipsychotic or antidepressant and an histamine H3 receptor antagonist for the prevention of psychotropic adverse effects
ACCESSION NUMBER: 2005:589 CAPLUS Full-text
DOCUMENT NUMBER: 142:79960
TITLE: New psychiatric drug formulation with an antipsychotic or antidepressant and an histamine H3 receptor antagonist for the prevention of psychotropic adverse effects
INVENTOR(S): Schwartz, Jean Charles; Rousseau Lecomte, Jeanne Marie
PATENT ASSIGNEE(S): Bioprojet, Fr.
SOURCE: Fr. Demande, 32 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

FR 2856596	A1	20041231	FR 2003-7836	20030627	
FR 2856596	B1	20070427			
CA 2530381	A1	20050106	CA 2004-2530381	20040625	
WO 2005000315	A1	20050106	WO 2004-FR1628	20040625	

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

```
L27           0 S L26 AND (PY<2003 OR AY<2003 OR PRY<2003)
L28        2840 S L20
L29          85 S L20 AND HISTAMINE?
L30         152 S L20 AND ?HISTAMINE?
L31          41 S L30 AND (PY<2003 OR AY<2003 OR PRY<2003)
```

L31 ANSWER 10 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN

TI Substance to prevent or reverse weight gain induced by psychoactive agents

ACCESSION NUMBER:	2003:396456 CAPLUS Full-text
DOCUMENT NUMBER:	138:379255
TITLE:	Substance to prevent or reverse weight gain induced by psychoactive agents
INVENTOR(S):	Miller, Jon M.
PATENT ASSIGNEE(S):	USA
SOURCE:	U.S. Pat. Appl. Publ., 5 pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20030096808 A1 20030522 US 1999-280279
19990329 <--
PRIORITY APPLN. INFO.: US 1999-280279
19990329 <--
AB A substance to prevent or reverse weight gain induced by psychoactive agents comprises an antipsychotic drug or mood stabilizing drug in a concentration from 0.01% to 99.99% in combination with a histamine H2-receptor antagonist in a concentration from 99.99% to 0.01%. Example antipsychotic drugs are olanzapine, clozapine, risperidone, and quetiapine. The antipsychotic drug is typically in a concentration of 10% to 90%, 30% to 60% and 50%. Example mood stabilizing drugs are divalproex sodium, valproic acid, and mirtazapine. The mood stabilizing drug is typically in a concentration of 10% to 90%, 30% to 60% and 50%. Example histamine H2-receptor antagonist are nizatidine, famotidine, cimetidine and ranitidine. The histamine H2-receptor antagonist (16) is typically in a concentration of 60% to 30% and 50%.
IC ICM A61K031-551

L31 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN
TI Bodyweight gain with atypical antipsychotics: A comparative review
ACCESSION NUMBER: 2001:141908 CAPLUS Full-text
DOCUMENT NUMBER: 135:161867
TITLE: Bodyweight gain with atypical antipsychotics: A comparative review
AUTHOR(S): Wetterling, Tilman
CORPORATE SOURCE: Department of Psychiatry and Psychotherapy, Johann
Wolfgang Goethe University, Frankfurt, Germany
SOURCE: Drug Safety (2001), 24(1), 59-73
CODEN: DRSAEA; ISSN: 0114-5916
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 93 refs. The atypical antipsychotics have been shown to have superior efficacy compared with typical antipsychotics such as haloperidol, particularly in the treatment of neg. symptoms of schizophrenia. Furthermore, they induce less extrapyramidal effects. However, following clin. use, marked bodyweight gain has been frequently observed with some of the atypical antipsychotic drugs. In order to examine and compare the frequency, amount and conditions of bodyweight gain during treatment with atypical antipsychotics, studies concerning bodyweight gain with these agents were identified through a MEDLINE search from 1966 to Mar. 2000. Although comparison is limited by the different designs and recruitment procedures of the reviewed studies, the available data support the notion that the frequency as well as the amount of bodyweight gain is high in patients treated with olanzapine (average bodyweight gain 2.3 kg/mo), clozapine (1.7 kg/mo), quetiapine (1.8 kg/mo), and possibly also zotepine (2.3 kg/mo). Moderate changes in bodyweight have been observed in the treatment with risperidone (average bodyweight gain 1.0 kg/mo). Ziprasidone seems to induce only slight bodyweight changes (0.8 kg/mo). Bodyweight gain most frequently occurs in the first 12 wk of treatment. Patients who

were underweight at the beginning of treatment are at highest risk, of gaining bodyweight. The underlying pathomechanism still remains largely unclear. The relative receptor affinities of the atypical antipsychotics for histamine H1 receptors as well as the ratio of their affinity for serotonin 5-HT2 and dopamine D2 receptors appear to be the most robust correlate of bodyweight gain. Furthermore, the induction of leptin secretion may have an important impact on bodyweight gain in patients treated with atypical antipsychotics. Although many questions concerning the pathogenesis of bodyweight gain remain unresolved, this adverse effect has to be taken into consideration when prescribing the atypical antipsychotics, particularly in view its affect on compliance during long term treatment and the long term effects of obesity on mortality and morbidity.

L31 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN
TI Combination for treating weight gain associated with antipsychotic use
comprising an atypical antipsychotic and an H2 antagonist
ACCESSION NUMBER: 2000:881023 CAPLUS Full-text
DOCUMENT NUMBER: 134:33017
TITLE: Combination for treating weight gain associated with
antipsychotic use comprising an atypical antipsychotic
and an H2 antagonist
INVENTOR(S): Todd, Jane Rogers
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000074784	A1	20001214	WO 2000-US9811	20000522 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1189662	A1	20020327	EP 2000-931932	20000522 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

L31 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2009 ACS on STN
TI H2 antagonist nizatidine may control olanzapine-associated weight gain in
schizophrenic patients
ACCESSION NUMBER: 2000:489015 CAPLUS Full-text
DOCUMENT NUMBER: 134:13255
TITLE: H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic
patients
AUTHOR(S): Sacchetti, E.; Guarneri, L.; Bravi, D.
CORPORATE SOURCE: University Psychiatric Service, University School of
Medicine & Spedali Civili, Brescia, Italy
SOURCE: Biological Psychiatry (2000), 48(2), 167-168
CODEN: BIPCBF; ISSN: 0006-3223
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Background: Olanzapine is temporally associated, in a number of patients with schizophrenia, with weight gain. H2 antagonists, like nizatidine, have been shown to control appetite in overweight patients. Methods: A patient with olanzapine temporally associated weight gain was treated with nizatidine as "add-on" therapy. Results: Nizatidine treatment was associated with good control and subsequent reduction of weight after 4 to 5 wk of therapy in a patient with repetitive episodes of weight gain during olanzapine treatment. Olanzapine was otherwise well tolerated and effective in controlling psychopathol. Conclusions: H2 antagonist treatment with olanzapine may be a valid medical strategy in preventing and/or reducing weight gain in patients with schizophrenia. Controlled studies are recommended to confirm this observation.
CC 1-11 (Pharmacology)
ST nizatidine histamine antagonist antiobesity olanzapine schizophrenia
IT Antihistamines
(H2; H2 antagonist nizatidine may control olanzapine-associated weight gain
in schizophrenic humans)
IT 132539-06-1, Olanzapine
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(H2 antagonist nizatidine may control olanzapine-associated weight gain in
schizophrenic humans)

=> e schwartz jean?/au
E121 1 SCHWARTZ JEAN P/AU
E122 4 SCHWARTZ JEAN PIERRE/AU

```
E123          0 --> SCHWARTZ JEAN?/AU
E124          5     SCHWARTZ JEANNA/AU
E125          5     SCHWARTZ JEFF/AU
E126          2     SCHWARTZ JEFFERY/AU
E127          1     SCHWARTZ JEFFERY H/AU
E128          7     SCHWARTZ JEFFERY L/AU
E129          1     SCHWARTZ JEFFERY S/AU
E130          1     SCHWARTZ JEFFFREY/AU
E131        274     SCHWARTZ JEFFREY/AU
E132          1     SCHWARTZ JEFFREY A/AU

=> e lecomte jeanne?/au
E133          7     LECOMTE JEANNE M/AU
E134         72     LECOMTE JEANNE MARIE/AU
E135          0 --> LECOMTE JEANNE?/AU
E136         13     LECOMTE JEROME/AU
E137          1     LECOMTE JOAN/AU
E138          1     LECOMTE JOSEPH/AU
E139          1     LECOMTE JOULIN V/AU
E140          5     LECOMTE JULIE/AU
E141          2     LECOMTE JULIETTE/AU
E142          1     LECOMTE JULIETTE T/AU
E143         76     LECOMTE JULIETTE T J/AU
E144          1     LECOMTE JULIETTE THERESE J/AU

=> s e133-e134
              7 "LECOMTE JEANNE M"/AU
             72 "LECOMTE JEANNE MARIE"/AU
L32          79 ("LECOMTE JEANNE M"/AU OR "LECOMTE JEANNE MARIE"/AU)

=> s l32 and histiamine?
              5 HISTIAMINE?
L33           0 L32 AND HISTIAMINE?

=> s l32 and (py<2003 or ay<2003 or pry<2003)
       22984276 PY<2003
        4508246 AY<2003
        3977805 PRY<2003
L34          62 L32 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> s l32 and l23
L35           5 L32 AND L23

=> s l35 and (py<2003 or ay,2003 or pry<2003)
       22984276 PY<2003
           3432 AY
             40 AYS
           3472 AY
                  (AY OR AYS)
          44526 2003
              0 AY,2003
                  (AY(W)2003)
        3977805 PRY<2003
L36           1 L35 AND (PY<2003 OR AY,2003 OR PRY<2003)

=> s l35 and (py<2003 or ay<2003 or pry<2003)
       22984276 PY<2003
```

```
       4508246 AY<2003
       3977805 PRY<2003
L37          1 L35 AND (PY<2003 OR AY<2003 OR PRY<2003)
```